Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Teva Pharmaceutical Industries Ltd

NYSE: TEVA · Life Sciences · 11 alerts · CIK 818686

Share price
$42.57Close, Nov 16
Market cap
$49.7B
Shares outstanding
1.17BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Teva Pharmaceutical Industries Ltd filings on SEC EDGAR ↗

4:16 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries EVP, Europe Commercial Richard Daniell Sells $1.93M of Stock

Richard Daniell, EVP, Europe Commercial, sold 45,003 shares of Teva Pharmaceutical Industries Ltd at $42.80 to $42.91 a share (average $42.86) in 2 transactions, worth $1.93M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 55,755 (-26.4%).

Value
$1.93M
Shares
45,003
Average price
$42.86
Role
EVP, Europe Commercial
Holding change
-26.4%
Trade date
Nov 9, 2026 to Nov 11, 2026
4:14 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries President and CEO Richard D. Francis Sells $10.6M of Stock

Richard D. Francis, President and CEO, sold 250,000 shares of Teva Pharmaceutical Industries Ltd at $42.24 a share, worth $10.6M in total on Nov 10, 2026. Shares held after the trade: 927,529 (-21.2%).

Value
$10.6M
Shares
250,000
Price
$42.24
Role
President and CEO
Holding change
-21.2%
Trade date
Nov 10, 2026
4:12 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries See "Remarks" Mark Sabag Sells $1.97M of Stock

Mark Sabag, See "Remarks", sold 44,710 shares of Teva Pharmaceutical Industries Ltd at $44.14 a share, worth $1.97M in total on Nov 12, 2026. Shares held after the trade: 80,760 (-35.6%).

Value
$1.97M
Shares
44,710
Price
$44.14
Role
See "Remarks"
Holding change
-35.6%
Trade date
Nov 12, 2026
4:11 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries CAO Amir Weiss Sells $744K of Stock

Amir Weiss, CAO, sold 17,289 shares of Teva Pharmaceutical Industries Ltd at $43.03 to $43.15 a share (average $43.04) in 3 transactions, worth $744K in total on Nov 9, 2026. Shares held after the trade: 3,537 (-72.9%).

Value
$744K
Shares
17,289
Average price
$43.04
Role
CAO
Holding change
-72.9%
Trade date
Nov 9, 2026
4:04 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries See "Remarks" Mark Sabag Sells $1.93M of Stock

Mark Sabag, See "Remarks", sold 46,000 shares of Teva Pharmaceutical Industries Ltd at $41.93 a share, worth $1.93M in total on Nov 5, 2026. Shares held after the trade: 80,760 (-36.3%).

Value
$1.93M
Shares
46,000
Price
$41.93
Role
See "Remarks"
Holding change
-36.3%
Trade date
Nov 5, 2026
4:02 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries Interim Cheif Legal Officer Dov Bergwerk Sells $1.1M of Stock

Dov Bergwerk, Interim Cheif Legal Officer, sold 26,260 shares of Teva Pharmaceutical Industries Ltd at $41.72 a share, worth $1.1M in total on Nov 4, 2026. Shares held after the trade: 11,943 (-42.3%).

Value
$1.1M
Shares
26,260
Average price
$41.72
Role
Interim Cheif Legal Officer
Holding change
-42.3%
Trade date
Nov 4, 2026
8:09 AM ET 8-K
Financial Results

Teva Pharmaceutical Industries Financial Results

Teva Pharmaceutical Industries reported Q3 2026 revenues of $4.4 billion, a 2% decrease year-over-year due to competition for its generic Revlimid, offset by 33% growth in its innovative brand portfolio. The company raised its full-year 2026 revenue outlook for key brands AUSTEDO, AJOVY, and UZEDY following strong quarterly performance and gross margin expansion.

Term
Q3 2026

“Teva’s Pivot to Growth strategy is delivering strong results, as evidenced by the 33% growth across our key innovative brands and the substantial expansion of our non-GAAP gross profit margin to its highest level in a decade. We are strengthening our neuroscience leadership with the launch of WELTRUZA™ and the strategic addition of BXCL-501, while our biosimilars business is set to achieve its 2027 revenue goal a year ahead of schedule.”

Richard Francis, Teva's President and CEO
5:09 PM ET 8-K
Leadership Change

Teva Pharmaceutical Industries Leadership Change

Teva Pharmaceutical Industries appointed Dr. David J. Brailer to its Board of Directors, effective November 3, 2026. Dr. Brailer, an independent director with extensive health-tech and policy experience, will serve on the Human Resources and Compensation and Compliance Committees until the 2027 annual meeting.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.